News
Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...
22h
Zacks Investment Research on MSNCI's Unit Unveils Offering to Expand Access to GLP-1 MedicationsThe health services arm of The Cigna Group CI, Evernorth, recently introduced a pharmacy benefit offering designed to enhance ...
As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results